VivoSeq
Oncology

Tumour

0

Pipeline Programs↗

10

Active Trials↗

6

Companies Involved↗

Tumour is an early-stage landscape with 0 programs across 6 companies. The most active players are Boehringer Ingelheim, Lytix Biopharma AS, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

73/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalL

Lytix Biopharma AS

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

PreclinicalC

Crescendo Biologics Ltd.

0 programs

PreclinicalB

Blue Earth Therapeutics Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed8 · 33%
Recruiting6 · 25%
Terminated3 · 13%
Active, not recruiting2 · 8%
Not yet recruiting2 · 8%
Unknown status2 · 8%
Other1 · 4%

Clinical Trials

Trial Activity

24 trials

Lutathera and ASTX727 in Neuroendocrine Tumours
Recruiting·IImperial College London·Phase 1·NCT05178693·27 enrolled
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Recruiting·BBritish Columbia Cancer Agency·Phase 2·NCT04273061·200 enrolled
Dynamic Changes in Circulating Tumour Cells Protein Expression
Recruiting·—·Phase 2·NCT06314997·150 enrolled
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1·NCT06632236·12 enrolled
5G-PEARL: Paxalisib in Malignant Brain Tumours
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT07391215·64 enrolled
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Recruiting·BBlue Earth Therapeutics Ltd·Phase 1/2·NCT05413850·82 enrolled
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05916313·18 enrolled
Paediatric Hepatic International Tumour Trial
Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT03017326·450 enrolled
The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours
Not yet recruiting·UUniversity College, London·Phase 2·NCT06678867·80 enrolled
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
Not yet recruiting·TThe Christie NHS Foundation Trust·Phase 2·NCT06470880·40 enrolled
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
Completed·AAB Science·Phase 2·NCT01506336·44 enrolled
An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours
Completed·GGalderma R&D·Phase 3·NCT01541930·21 enrolled
Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
Completed·LLytix Biopharma AS·Phase 1·NCT01058616·14 enrolled
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00385203·35 enrolled
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Completed·Ipsen logoIpsen·Phase 4·NCT02075606·50 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)